Stifel Resumes Innate Pharma Coverage With Buy Rating
Stifel resumed coverage of Innate Pharma with a Buy rating and a EUR 6 price target.
Related stories
Advanced Info Service Reports Quarterly Revenue of 58.06 Billion Baht
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Cosmo First Q2 Consolidated Revenue From Operations INR 13,878.6 Million
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Cosmo First Reports Q2 Consolidated Net Profit of INR 985.8 Million
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
Advanced Info Service Reports Quarterly Profit of 13.50 Billion Baht
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
TSX Futures Slip as Oil Rebounds; US Midterms in Focus
Canadian stock futures slipped as oil rebounded, with US midterm elections in focus.
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC
S&P/TSX Futures Fall 0.4% as Oil Rebounds and US Midterms Draw Focus
December S&P/TSX futures were down 0.4% at 5:41 a.m. ET as oil rebounded on dimmer hopes for a Middle East peace deal. Investors also watched the US midterm elections.
M impact | EQUITY | Nov 03, 2026, 10:53 AM UTC